Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Table 3 Risk factors for OS, DFS, TRM and relapse incidence

	OS		DFS		TRM		Relapse rate
	Univariate	Multivariate (RR)	Univariate	Multivariate (RR)	Univariate	Multivariate (RR)	Univariate	Multivariate (RR)
Sex male/female	NS	NS	NS	NS	NS	NS	NS	NS
Genetic subgroups favorable/intermediate/poor risk/unknown	NS	NS	NS	NS	NS	NS	P = 0.002	P = 0.018 (2.218)
Age ≤30.5/>30.5 years	NS	NS	NS	NS	NS	NS	NS	NS
Induction Chemotherapy cycles ≤1/>1 cycles	NS	NS	NS	NS	NS	NS	NS	NS
Consolidation chemotherapy cycles ≤2/>2 cycles	NS	NS	NS	NS	NS	NS	NS	NS
Source of stem cells PB /BM + PB	NS	NS	NS	NS	NS	NS	NS	NS
Source of donors related/unrelated	NS	NS	NS	NS	NS	NS	NS	NS
Age of donors ≤30.0/>30.0 years	NS	NS	NS	NS	P = 0.026	NS	NS	NS
HLA typing matched/mismached	NS	NS	NS	NS	NS	NS	P = 0.011	NS
Conditioning regimen BuCy/BuFlu	NS	NS	NS	NS	NS	NS	NS	NS
MNC(10⁸/Kg) ≤7.33/>7.33	NS	NS	NS	NS	NS	NS	NS	NS
CD34 + (10⁶/Kg) ≤6.22/>6.22	NS	NS	NS	NS	NS	NS	NS	NS
Acute GVHD With/without	P = 0.014	P = 0.018 (5.214)	NS	NS	P = 0.001	P = 0.006 (18.538)	NS	NS
Chronic GVHD With/without	NS	NS	NS	NS	NS	NS	NS	NS

Abbreviations: OS, overall survival; DFS, disease free survival; TRM, transplant related mortality; BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-fludarabine; BM, bone marrow; PB, peripheral blood; MNC, mononucleated cell.

ISSN: 1756-8722